An exploratory analysis of mitochondrial haplotypes and allogeneic hematopoietic cell transplantation outcomes

Julie A. Ross, Jakub Tolar, Logan G. Spector, Todd DeFor, Troy C. Lund, Daniel J. Weisdorf, Erica Langer, Anthony J. Hooten, Bharat Thyagarajan, Michelle K. Gleason, John E. Wagner, Kimberly Robien, Michael R. Verneris

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Certain mitochondrial haplotypes (mthaps) are associated with disease, possibly through differences in oxidative phosphorylation and/or immunosurveillance. We explored whether mthaps are associated with allogeneic hematopoietic cell transplantation (HCT) outcomes. Recipient (n= 437) and donor (n= 327) DNA were genotyped for common European mthaps (H, J, U, T, Z, K, V, X, I, W, and K2). HCT outcomes for mthap matched siblings (n= 198), all recipients, and all donors were modeled using relative risks (RR) and 95% confidence intervals and compared with mthap H, the most common mitochondrial haplotypes. Siblings with I and V were significantly more likely to die within 5 years (RR= 3.0; 95% confidence interval [CI], 1.2 to 7.9; and RR= 4.6; 95% CI, 1.8 to 12.3, respectively). W siblings experienced higher acute graft-versus-host disease (GVHD) grades II to IV events (RR= 2.1; 95% CI, 1.1 to 2.4) with no events for those with K or K2. Similar results were observed for all recipients combined, although J recipients experienced lower GVHD and higher relapse. Patients with I donors had a 2.7-fold (1.2 to 6.2) increased risk of death in 5 years, whereas few patients with K2 or W donors died. No patients with K2 donors and few patients with U donors relapsed. Mthap may be an important consideration in HCT outcomes, although validation and functional studies are needed. If confirmed, it may be feasible to select donors based on mthap to increase positive or decrease negative outcomes.

Original languageEnglish (US)
Pages (from-to)81-88
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Issue number1
StatePublished - Jan 1 2015

Bibliographical note

Funding Information:
Supported by Children's Cancer Research Fund Hodder Chair (J.A.R.); NIH T32 CA099936 (J.A.R.); NIH K05 CA157439 (J.A.R.), R21 CA135180 (K.R.), and the Tulloch Chair in Stem Cell Biology, Genetics, and Genomics (J.T.).

Publisher Copyright:
© 2015 American Society for Blood and Marrow Transplantation.


  • Graft-versus-host disease
  • Hematopoietic cell transplantation
  • Mitochondria
  • Polymorphism


Dive into the research topics of 'An exploratory analysis of mitochondrial haplotypes and allogeneic hematopoietic cell transplantation outcomes'. Together they form a unique fingerprint.

Cite this